Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of Net Margin readings, the most recent being 42.66% for Q1 2026.

  • On a quarterly basis, Net Margin rose 254.0% to 42.66% in Q1 2026 year-over-year; TTM through Mar 2026 was 35.94%, a 80.0% increase, with the full-year FY2025 number at 35.24%, up 383.0% from a year prior.
  • Net Margin hit 42.66% in Q1 2026 for Catalyst Pharmaceuticals, up from 30.1% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 56.38% in Q4 2022 to a low of 29.96% in Q3 2023.
  • Median Net Margin over the past 5 years was 34.64% (2023), compared with a mean of 31.37%.
  • Biggest five-year swings in Net Margin: plummeted -6970bps in 2023 and later skyrocketed 6406bps in 2024.
  • Catalyst Pharmaceuticals' Net Margin stood at 56.38% in 2022, then plummeted by -73bps to 15.41% in 2023, then surged by 113bps to 32.78% in 2024, then dropped by -8bps to 30.1% in 2025, then skyrocketed by 42bps to 42.66% in 2026.
  • The last three reported values for Net Margin were 42.66% (Q1 2026), 30.1% (Q4 2025), and 35.57% (Q3 2025) per Business Quant data.